Hologic, Inc. $HOLX Stake Lessened by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 48.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,978 shares of the medical equipment provider’s stock after selling 14,000 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Hologic were worth $1,011,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Winnow Wealth LLC acquired a new stake in shares of Hologic in the 3rd quarter valued at about $26,000. Root Financial Partners LLC bought a new stake in Hologic in the third quarter valued at about $27,000. Caitong International Asset Management Co. Ltd raised its stake in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares in the last quarter. SJS Investment Consulting Inc. lifted its holdings in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 362 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its position in shares of Hologic by 168.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 310 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

NASDAQ HOLX opened at $75.02 on Tuesday. The company has a 50-day moving average price of $74.88 and a two-hundred day moving average price of $71.38. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.36. The stock has a market cap of $16.75 billion, a price-to-earnings ratio of 31.26, a price-to-earnings-growth ratio of 2.23 and a beta of 0.72. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm posted $0.87 EPS. The business’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on HOLX shares. BTIG Research restated a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 price target on shares of Hologic in a research report on Wednesday, October 22nd. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Morgan Stanley raised their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Finally, Stephens lowered Hologic from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $78.00 to $76.00 in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.